Clinical Trials
13 trialsNCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT06616584 2026-05-05
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Recruiting
NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05704634 2026-04-15
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06943664 2026-03-24
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
NCT07450183 2026-03-04
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Henry Ford Health System
Phase 2 Not yet recruiting
NCT06918132 2026-02-24
N-PLANC
Mayo Clinic
Phase 2 Recruiting
NCT06465329 2026-02-12
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT06731270 2026-02-12
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
Phase 2 Recruiting
NCT06923761 2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2 Recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting